86P - Overview of breast cancer management: Yangon private sector cancer care

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Breast Cancer, Early Stage
Presenter Shu Mon
Citation Annals of Oncology (2016) 27 (suppl_9): ix19-ix29. 10.1093/annonc/mdw575
Authors S. Mon1, T.T. Aye1, M. Khine2, E.P.P. Aung2, A.S. Nyunt2, P.T. Hnin2, S.S. Htay1, N. Sein1, E. Khaing2
  • 1Oncology Department, Bahosi Medical Centre Bahosi Housing Complex, 11131 - Yangon/MM
  • 2Oncology, Thurein Oncology Clinic, 11131 - Yangon/MM

Abstract

Background

With the development of advanced technology in the field of oncology, breast cancer treatment becomes individualized nowadays. Breast cancer is the commonest cancer in Myanmar women. Aim of this study is to explore about breast cancer treatment in private sector cancer care in Yangon, Myanmar.

Methods

Clinical data of breast cancer patients registered at 3 private clinics in Yangon, Myanmar from July 2014 to June 2016 were studied and analyzed.

Results

Including 2 male breast cancer patients, a total of 488 breast cancer patients were registered. Mean age is 52.73 yrs (range 22yrs - 87yrs). 13.53% (n = 66) were young age patients under age of 40. Most patients were diagnosed at Stage II = 65.57% (n = 320) and Stage III=18.85% (n = 92).82.5% (n = 407) were investigated for biological markers (Estrogen, progesterone receptors and Her2) using immunohistochemistry method whereas 8.23% were not done the test due to financial limitations. Ki 67, P53 status were done in only 11.47% (n = 56). Molecular subtypes were ER positive HER2 negative in 39.8% (n = 162), Her2 positive in 37.59% (n = 154) and Triple Negative Breast cancer in 17.93% (n = 73).Total mastectomy and axillary clearance was done in 94.03% (n = 459). Breast conserving surgery was done in 3.8% (n = 15). Sentinel Lymph node Biopsy was done in 3.6% (n = 18).Breast reconstruction surgery was done in 0.61% (n = 3). Radiation treatment was done in 12.09% (n = 59). Neoadjuvant and adjuvant chemotherapy using different regimes were done in 96.72%(n = 472). Among Her2 positive patients, 27.27% (n = 42) can afford for anti Her2 targeted therapy. Hormonal therapy using Tamoxifen or Aromatase Inhibitors was given to all ER positive cases depend on menopausal status.

Conclusions

Total mastectomy and axillary lymph node dissection was the treatment of choice in surgical management due to patients preference and limitations to access radiation therapy. Limited number of Her2 positive patients received molecular targeted therapy due to financial difficulities. Overall, access to treatment, financial limitations and insufficient health care system are the barriers to get standard treatment in breast cancer in Myanmar.

Clinical trial indentification

Legal entity responsible for the study

Thurein Clinic, Yangon

Funding

Thurein Clinic, Yangon

Disclosure

All authors have declared no conflicts of interest.